Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters)

Albert Fournier; Roxana Oprisiu; Jean Michel Achard; Olaf H. Klungel; Hubert G. M. Leufkens; Anthonius De Boer; W.T. Longstreth Jr.; Robert C. Kaplan; Nicholas L. Smith; Bruce M. Psaty

doi:10.1001/archinte.161.17.2152

Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters)

Albert Fournier
, Roxana Oprisiu
, Jean Michel Achard
, Olaf H. Klungel
, Hubert G. M. Leufkens
, Anthonius De Boer
, W.T. Longstreth Jr.
, Robert C. Kaplan
, Nicholas L. Smith
, Bruce M. Psaty

Pharmacoepidemiology and Clinical Pharmacology

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	2152-2153
Number of pages	2
Journal	Archives of Internal Medicine
Volume	161
Issue number	17
DOIs	https://doi.org/10.1001/archinte.161.17.2152
Publication status	Published - 24 Sept 2001

Keywords

acetylsalicylic acid
amiloride
antihypertensive agent
beta adrenergic receptor blocking agent
calcium antagonist
captopril
diltiazem
dipeptidyl carboxypeptidase inhibitor
hydrochlorothiazide
hydroxymethylglutaryl coenzyme A reductase inhibitor
propranolol
ramipril
thiazide diuretic agent
antihypertensive therapy
brain protection
cardiovascular disease
case control study
clinical trial
combination chemotherapy
drug effect
heart atrium
heart left ventricle function
human
hypertension
letter
monotherapy
primary prevention
priority journal
risk
secondary prevention
cerebrovascular accident

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/archinte.161.17.2152

Cite this

Fournier, A., Oprisiu, R., Michel Achard, J., Klungel, O. H., Leufkens, H. G. M., De Boer, A., Longstreth Jr., W. T., Kaplan, R. C., Smith, N. L., & Psaty, B. M. (2001). Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters). Archives of Internal Medicine, 161(17), 2152-2153. https://doi.org/10.1001/archinte.161.17.2152

@article{4c64895bb26b4766aa0bd162501dcb58,

title = "Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters)",

keywords = "acetylsalicylic acid, amiloride, antihypertensive agent, beta adrenergic receptor blocking agent, calcium antagonist, captopril, diltiazem, dipeptidyl carboxypeptidase inhibitor, hydrochlorothiazide, hydroxymethylglutaryl coenzyme A reductase inhibitor, propranolol, ramipril, thiazide diuretic agent, antihypertensive therapy, brain protection, cardiovascular disease, case control study, clinical trial, combination chemotherapy, drug effect, heart atrium, heart left ventricle function, human, hypertension, letter, monotherapy, primary prevention, priority journal, risk, secondary prevention, cerebrovascular accident",

author = "Albert Fournier and Roxana Oprisiu and \{Michel Achard\}, Jean and Klungel, \{Olaf H.\} and Leufkens, \{Hubert G. M.\} and \{De Boer\}, Anthonius and \{Longstreth Jr.\}, W.T. and Kaplan, \{Robert C.\} and Smith, \{Nicholas L.\} and Psaty, \{Bruce M.\}",

year = "2001",

month = sep,

day = "24",

doi = "10.1001/archinte.161.17.2152",

language = "English",

volume = "161",

pages = "2152--2153",

journal = "Archives of Internal Medicine",

issn = "0003-9926",

publisher = "American Medical Association",

number = "17",

}

Fournier, A, Oprisiu, R, Michel Achard, J, Klungel, OH , Leufkens, HGM , De Boer, A, Longstreth Jr., WT, Kaplan, RC, Smith, NL & Psaty, BM 2001, 'Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters)', Archives of Internal Medicine, vol. 161, no. 17, pp. 2152-2153. https://doi.org/10.1001/archinte.161.17.2152

Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters). / Fournier, Albert; Oprisiu, Roxana; Michel Achard, Jean et al.
In: Archives of Internal Medicine, Vol. 161, No. 17, 24.09.2001, p. 2152-2153.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters)

AU - Fournier, Albert

AU - Oprisiu, Roxana

AU - Michel Achard, Jean

AU - Klungel, Olaf H.

AU - Leufkens, Hubert G. M.

AU - De Boer, Anthonius

AU - Longstreth Jr., W.T.

AU - Kaplan, Robert C.

AU - Smith, Nicholas L.

AU - Psaty, Bruce M.

PY - 2001/9/24

Y1 - 2001/9/24

KW - acetylsalicylic acid

KW - amiloride

KW - antihypertensive agent

KW - beta adrenergic receptor blocking agent

KW - calcium antagonist

KW - captopril

KW - diltiazem

KW - dipeptidyl carboxypeptidase inhibitor

KW - hydrochlorothiazide

KW - hydroxymethylglutaryl coenzyme A reductase inhibitor

KW - propranolol

KW - ramipril

KW - thiazide diuretic agent

KW - antihypertensive therapy

KW - brain protection

KW - cardiovascular disease

KW - case control study

KW - clinical trial

KW - combination chemotherapy

KW - drug effect

KW - heart atrium

KW - heart left ventricle function

KW - human

KW - hypertension

KW - letter

KW - monotherapy

KW - primary prevention

KW - priority journal

KW - risk

KW - secondary prevention

KW - cerebrovascular accident

U2 - 10.1001/archinte.161.17.2152

DO - 10.1001/archinte.161.17.2152

M3 - Letter

SN - 0003-9926

VL - 161

SP - 2152

EP - 2153

JO - Archives of Internal Medicine

JF - Archives of Internal Medicine

IS - 17

ER -